Exelixis reports prostate cancer trial results from expanded cohort

 The combination of cabozantinib and atezolizumab evaluated in cohort 6 of the COSMIC-021 phase 1b trial resulted in objective response rates of 27% and 18% per investigator assessment and Blinded Independent Radiology Committee, respectively –

– Exelixis intends to discuss the results with the U.S. FDA to determine next steps toward a regulatory submission for the combination regimen for patients with high-risk metastatic CRPC –

– Phase 3 CONTACT-02 trial underway for metastatic CRPC –

https://www.businesswire.com/news/home/20210524005761/en/Exelixis-Announces-Phase-1b-Results-from-Cohort-6-of-COSMIC-021-Trial-in-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer